Based on an animal model of oxidative stress-induced AMD, PTX3 has been proposed to inhibit AP activation (and the subsequent complement-dependent inflammation) via recruitment of FH (Wang et al., 2016). Here, PTX3 is linked to age-related macular degeneration.